New York: The Covid-19 candidate vaccine evolved through the University of Oxford in partnership with UK-based biopharmaceutical company AstraZeneca has achieved a Phase 3 trial in the United States.
The trial will recruit about 30,000 adult volunteers at 80 sites in the United States to assess whether the candidate vaccine, known as AZD1222, can prevent it from symptomatic Covid-19, the US National Institutes of Health announced Monday. U. S. A. (NIH).
“The effects of preclinical studies conducted through NIH scientists have supported the immediate progression of this candidate vaccine, which has also shown promise in early-stage clinical trials,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is a component of NIH, said in a statement.
The Phase 3 test is being implemented from Operation Warp Speed, a multi-agency collaboration led through the US Department of Health and Human Services. But it’s not the first time To promote the development, manufacture and distribution of medical countermeasures for Covid-19.
The main objective of the trial is to determine whether AZD1222 can prevent symptomatic Covid-19 after two doses. -19.
It will also be evaluated whether the experimental vaccine may cause visits to emergency branches due to Covid-19.
Participants are randomly assigned to obtain two doses of AZD1222 or saline control, 4 weeks apart, with twice as many participants receiving the vaccine as saline control.
The Jenner Institute of the University of Oxford and the Oxford Vaccine Group have developed AZD1222, the candidate vaccine authorized to AstraZeneca for further development.
The vaccine uses an unrepeatable chimpanzee adenovirus to administer a SARS-CoV-2 protein to induce an immune response.
SARS-CoV-2 is the virus that causes Covid-19.
AstraZeneca said it continues to interact with governments, multilateral organizations and partners around the world to ensure broad and equitable access to the vaccine, clinical trials are successful.
Recent announcements with Russia, South Korea, Japan, China, Latin America and Brazil bring global capacity to 3 billion doses of vaccines.
U. S. President Donald Trump is pressuring the Food and Drug Administration (FDA) to accelerate approval of Covid-19 and vaccines.
In an interview with the Financial Times published on Sunday, FDA Commissioner Stephen Hahn said that emergency authorization of the Covid-19 vaccine would possibly be the right solution if the benefits outweigh the risks.
Dear reader,
This segment is about life in the United Arab Emirates and facts you can’t live without.
Sign up to read and complete gulfnews. com